Gilead Sciences Announces Positive Data from NIAID Study of Remdesivir for COVID-19

May 1, 2020 by Mandy Qualls

Filed under COVID-19 for Employers, COVID-19 for the Workforce, For Employers, For the Workforce

Last modified May 4, 2020

April 29, 2020 — Gilead Sciences, a research-based pharmaceutical company, announced via press release some promising data concerning the experimental drug remdesivir.

“Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19,” the press release carefully states. However, the clinical trial led by the National Institute of Allergy and Infectious Disease (NIAID) showed positive data amongst a growing data set. NIAID will provide more detailed information at an upcoming briefing in the near future.

Share this

Related Articles

                            Leave a Comment